Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients

Completed

Conditions studied: Breast Cancer

In brief

The purpose of this study is to compare pre and post Aromatase Inhibitor (AI) treatment serological markers of inflammation and assess for correlation with AI-MS.

Key facts

Study ID

NCT01051609

Run by

Jonsson Comprehensive Cancer Center

People needed

27

Starts

2010-05-01

Last updated by the study team

2016-09-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women 18 years and older with non-metastatic hormone receptor (ER and/or PR) positive breast cancer who are eligible for and planning on starting treatment with an AI within one month of signing consent.
• Postmenopausal, defined as at least one of the following: a) amenorrhea for at least 12 months b) prior bilateral oophorectomy at least 2 years prior to trial registration.

You may not qualify if…

• History of autoimmune connective tissue disease, such as rheumatoid arthritis, lupus, or other autoimmune conditions affecting joints.
• Treatment with steroid (for any condition, except for chemotherapy premedication) within 30 days of trial registration.
• Prior treatment with an AI (patients previously or currently on tamoxifen are eligible as long as patients are off tamoxifen for 2 weeks prior to baseline blood draw)
• Active or ongoing infection
• Known metastatic disease
• Known history of HIV or hepatitis infections
• Ongoing radiation therapy (radiation must have been completed 2 weeks prior to starting treatment with an AI)
• Non-invasive (DCIS, LCIS) cancer only (no diagnosis of invasive cancer)
• Pregnant or lactating
• Unable to speak, read, and write in English

Where it is running

• UCLA Jonsson Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.